All Articles

On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Darzalex is the first and only CD38-directed antibody to receive regulatory approval for the treatment of patients with MM and is the first to be approved for the split-dosing regimen. This new regimen gives patients and healthcare providers the option to split the first dose of Darzalex over the course of 2 consecutive days, which has the benefit of shortening the duration of the first infusion.

About 2 years ago, the Academy of Oncology Nurse & Patient Navigators (AONN+) unveiled 35 evidence-based oncology navigation metrics.

Brianne Dart’s cancer journey began in 2006.

For patients with cancer, developing an individualized treatment plan requires a multidisciplinary team approach, and as the use of oral oncolytics increases, so does the need for effective communication between all oncology providers involved in patient care.

According to the National Comprehensive Cancer Network, clinical trials provide the best management of patients with cancer, but despite this, less than 10% of participants in clinical trials come from minority populations.

Patient education is vital to the successful administration of chimeric antigen receptor (CAR) T-cell immunotherapy.

The American Joint Committee on Cancer (AJCC) staging system is a classification system used to describe the extent of disease progression in patients with cancer.

Most men need to pay more attention to their health, according to Frank dela Rama, RN, MS, AOCNS, a clinical nurse specialist in oncology/genomics at Palo Alto Medical Foundation in California.

Bluebird Bio develops plan to sell gene-replacement therapy with annual payments contingent on continued effectiveness

This could be your year to join us, meet your fellow navigator colleagues, and strengthen your professional skills!